Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
14.55
-1.18 (-7.50%)
Dec 3, 2024, 1:58 PM EST - Market open
Intellia Therapeutics Employees
Intellia Therapeutics had 526 employees as of December 31, 2023. The number of employees decreased by 72 or -12.04% compared to the previous year.
Employees
526
Change (1Y)
-72
Growth (1Y)
-12.04%
Revenue / Employee
$81,913
Profits / Employee
-$992,935
Market Cap
1.48B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Schrödinger | 867 |
BioCryst Pharmaceuticals | 536 |
Immunocore Holdings | 497 |
Travere Therapeutics | 380 |
Kiniksa Pharmaceuticals International, | 297 |
Arcutis Biotherapeutics | 296 |
Nurix Therapeutics | 284 |
Ocular Therapeutix | 267 |
NTLA News
- 8 days ago - Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - GlobeNewsWire
- 14 days ago - Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade) - Seeking Alpha
- 17 days ago - Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis - GlobeNewsWire
- 22 days ago - Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus - Seeking Alpha
- 25 days ago - Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 27 days ago - Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024 - GlobeNewsWire